|
Last
updated February 16, 2005
Saturday, MAY 14
11:45am–2:45pm
4506—Update
in Neonatal/Pediatric Nutrition Support
PAS Mini Course
Chair:
Michael Narkewicz, Children's Hospital, Denver, CO; and
Mark Corkins, Riley Hospital for Children and Indiana
University, Indianapolis, IN
Nutrition is critical to the normal growth and
development of children. Our ability to supply nutrition
to ill infants has increased dramatically in the last half
of the twentieth century with the development of
parenteral nutrition (TPN) and commercially prepared
formulas. This advanced technology has also presented us
with new knowledge as new nutritional deficiencies were
discovered in patients on long-term TPN. The new
technology has also created new risks associated with the
supply of this nutrition. This session will explore some
of the micronutrients necessary in infant TPN and some of
the potential toxicities. The potential risks and new
information concerning enteral formulas for use in infants
will be presented.
Target Audience: Clinicians involved in the care of
ill infants that require nutrition support beyond standard
feedings.
Introduction
Michael
R. Narkewicz, University of Colorado Health Sciences
Center, Denver, CO
Cysteine, Choline and Carnitine: Are These Cs
Important to the Neonate?
Sandeep
K. Gupta, Riley Hospital for Children and Indiana
University, Indianapolis, IN
Aluminum Toxicity in TPN
Gordon
L. Klein, University of Texas Medical Branch, Galveston,
TX
TPN-Associated Liver Disease in the Neonate
Beth
Anne Carter, Baylor College of Medicine, Houston, TX
Fat Soluble Vitamin Requirements in the Neonate
Frank
R. Greer, University of Wisconsin and Meriter Hospital,
Madison, WI
Enteral Formula Safety
Mark
R. Corkins, Riley Hospital for Children, Indiana
University, Indianapolis, IN
Recent Advances in Neonatal Formulas
Jane
D. Carver, University of South Florida College of
Medicine, Tampa, FL
Discussion
11:45am–2:45pm
4549—Using
High-Fidelity Patient Simulators in Pediatric Training
PAS Educational Workshop
Leader:
Mark D. Adler, Chicago, IL; Co-leaders: Elizabeth (Betsy)
Hunt, Viva Jo Siddall, Jennifer L. Trainor
This workshop will offer three varied approaches to
the use of a high-fidelity human patient simulator (HPS)
in pediatrics. We will briefly introduce the participant
to HPS technology, its costs, and support needs. We will
demonstrate:
-
Use of a portable HPS in on-ward surprise mock code
drill at a tertiary care pediatric hospital.
-
Use of a pediatric HPS mannequin for pediatric
resident core competency evaluation.
-
Quick-hit scenarios—use of a simulator to instruct
larger groups. We will describe the use of brief
scenarios in which 2–3 trainees participate and a
larger group observe and rate the performance of the
active participants.
Participants will gain an understanding of current
ways pediatric programs are or could use an HPS system.
Objectives:
-
Learn what high-fidelity simulators can do from an
educational and evaluation standpoint.
-
Understand the benefits and limitations of pediatric
high-fidelity patient simulation.
Method of Instruction: We plan to bring a pediatric
simulator (PediaSIM ECS, METI, Sarasota, FL) to use as the
focal point of our session. We plan to demonstrate three
examples of teaching or evaluation approaches. Each
example will begin with a group discussion followed by a
demonstration of the method. Participants will have time
to interact with the simulator and will be involved in the
simulation examples.
Target Audience: Trainee, junior faculty, mid-level
faculty
1:00pm–3:00pm
4651—Brain
Injury
PAS Original Science Abstracts -
Poster Symposium
1:00pm–3:00pm
4652—Neonatal
Infectious Disease and Inflammation
PAS Original Science Abstracts -
Platform Session
1:00pm–3:00pm
4654—Pulmonary
Vascular Biology
PAS Original Science Abstracts -
Poster Symposium
3:15pm–5:15pm
4802—Traumatic
Brain Injury in Infants and Children
PAS Topic Symposium
Chair:
Patrick M. Kochanek, University of Pittsburgh School of
Medicine and Children's Hospital of Pittsburgh,
Pittsburgh, PA
This program will address state of the art
investigation in the area of traumatic brain injury in
infants and children. Novel studies of the molecular
biology and biochemistry of pediatric traumatic brain
injury will be presented including work studying human
samples (CSF, brain tissue) using molecular tools, such as
proteomics and state of the art magnetic resonance
spectroscopy. Novel therapies will also be addressed,
including an RCT of the application of mild or moderate
therapeutic hypothermia in severe pediatric traumatic
brain injury. Finally, studies addressing the use of serum
biomarkers in the assessment of infants presenting to
emergency departments and outpatient clinics with silent
brain injury from inflicted childhood neurotrauma (child
abuse) will also be presented.
Target Audience: Pediatric practitioners treating
patients with traumatic brain injury; pediatric scientists
carrying out research on patients with traumatic brain
injury or working with models of developmental brain
injury; general practitioners and other clinicians and
investigators who interface on any level with infants who
are victims of inflicted childhood neurotrauma (child
abuse).
Cellular and Molecular Mechanisms of Secondary Injury
in Pediatric Traumatic Brain Injury
Patrick
M. Kochanek, Safar Center for Resuscitation Research,
University of Pittsburgh School of Medicine, Pittsburgh,
PA
Randomized Controlled Trial of Hypothermia in
Pediatric Traumatic Brain Injury
P.
David Adelson, Children's Hospital of Pittsburgh,
Pittsburgh, PA
Spectroscope Applications in Pediatric Traumatic
Brain Injury
Stephen
Ashwal, Loma Linda University School of Medicine, Loma
Linda, CA
A New Approach to the Detection of Inflicted
Childhood Neurotrauma
Rachel
P. Berger, Children's Hospital of Pittsburgh, Pittsburgh,
PA
3:15pm–5:15pm
4843—Gastroenterology
PAS Original Science Abstracts -
Platform Session
3:15pm–5:15pm
4878—Medical
Simulation Technology—What Is It and What Can It Do for
You?
PAS Educational Workshop
Leader:
Joseph O. Lopreiato, Bethesda, MD; Co-leaders: Michael
Fitzgerald, Hilary M. Haftel, Mary D. Patterson
Medical simulation technology is a rapidly expanding
area of education in medicine. This expansion is due in
part to an expectation that training programs will assess
and document clinical skills over a wide range of
competencies. Many medical schools and some residency
programs are using simulation technologies to assess
clinical skills, professionalism, information gathering,
communication and trauma/resuscitation skills. This
workshop is designed for medical professionals involved in
the education of medical students, residents and fellows.
It is directed to those with an interest in the
educational potential of simulation technology and will
also be useful for those interested in learning about the
practical aspects of simulator program development.
Objectives:
-
Be able to describe the capabilities and optimal
applications of the various types of medical
simulation in the pediatric environment.
-
Understand the elements required to develop and
sustain a successful program including issues of
personnel, utilization and financing.
Method of Instruction: Minilectures and
demonstrations will be used to introduce participants to
the full range of simulation technology including
standardized patients, mechanical simulators and
computer-based virtual reality; videos and DVDs, as well
as actual simulation technology, will be used as feasible.
This will serve as a springboard for discussion of the
practical aspects of a patient simulator program. Large
and small group activities will explore how these
technologies may be utilized in assessing clinical skills,
evaluating competencies and evaluating the progress of
trainees. We will also address the elements required to
develop and sustain a successful simulation program
including issues of personnel, utilization and financing.
Hands-on demonstrations of hardware and software elements
used in simulation will allow participants to judge which
simulation technologies would best serve their needs.
Target Audience: Trainee, junior faculty, mid-level
faculty
Sunday, MAY 15
8:00am–10:00am
5101—ARDS:
New Pathways and Treatments
PAS Topic Symposium
Chairs:
Steven H. Abman, University of Colorado School of
Medicine, Denver, CO; and Alan Jobe, Cincinnati Children's
Hospital Medical Center, Cincinnati, OH
Acute respiratory distress syndrome (ARDS) remains a
leading cause of morbidity and death in critically ill
neonates, infants and children. ARDS is associated with
diverse clinical disorders, including sepsis, trauma,
aspiration and infection and is characterized by lung
inflammation, non-hydrostatic pulmonary edema and poor
lung compliance. Recent advances in the basic pathobiology
of lung injury have led to new insights into the etiology
and potential therapeutic approaches toward ARDS. In
addition, recent clinical studies have examined
differences between adult and pediatric ARDS, genetic
susceptibility factors that may increase the risk for ARDS,
interactive cellular and physiologic mechanisms that cause
progressive lung injury and the role of different
strategies of mechanical ventilation that can adversely or
favorably determine the clinical outcomes of patients with
ARDS. This symposium includes leading experts in the field
of lung biology and critical care who will present state
of the art information on basic pathophysiologic
mechanisms of ARDS and new therapeutic approaches. These
integrated topics are of marked interest to intensivists,
neonatologists, pulmonologists, infectious disease and
basic scientists in the field of lung biology.
Target Audience: Scientists and clinicians interested
in basic mechanisms underlying the pathophysiology of
acute lung injury and clinical strategies in the
management of acute hypoxemic respiratory failure in
neonates, infants and children.
New Insights into ARDS
Michael
A. Matthay, University of California San Francisco Medical
School, San Francisco, CA
Mechanisms of Tissue Injury in Sepsis/ARDS
Hector
R. Wong, Cincinnati Children's Hospital Medical Center,
Cincinnati, OH
Role of Permissive Hypercapnea in Acute Lung Injury
Brian
Kavanagh, Hospital for Sick Children, Toronto, ON, Canada
Novel Ventilator Strategies in ARDS
John
H. Arnold, Children's Hospital, Boston, MA
8:00am–10:00am
5102—Community-Acquired
Staphylococcal Disease: New Twists for a Traditional
Pediatric Pathogen
PAS/PIDS Hot Topic
Chairs:
Stephen I. Pelton, Boston University School of Medicine,
Boston, MA; and Sheldon L. Kaplan, Baylor College of
Medicine, Houston, TX
Community-acquired, methicillin-resistant
Staphylococcal disease has been reported with increasing
frequency from multiple geographic locations in the United
States over the past several years. This symposium will
present current data on the epidemiology, molecular
genetics and clinical aspects of these evolving pathogens,
as well as on infection control practices that may be
useful for prevention.
Target Audience: Scientists and clinicians from the
following disciplines: pediatric infectious disease,
community pediatricians, pediatric ER and public health.
Community-Acquired Staphylococcal Disease: New Twists
for a Traditional Pediatric Pathogen
Stephen
I. Pelton, Boston University School of Medicine, Boston,
MA
Epidemiology of Community-Acquired, Methicillin-Resistant
Staphylococcus aureus
Daniel
B. Jernigan, Centers for Disease Control and Prevention,
Atlanta, GA
The Molecular Basis For Epidemic Community-Onset MRSA
Robert
S. Daum, The University of Chicago, Chicago, IL
Clinical Implications of Community-Acquired,
Methicillin-Resistant Staphylocccus aureus
Sheldon
L. Kaplan, Baylor College of Medicine, Houston, TX
Prevention and Control of Methicillin-Resistant Staphylococcus
aureus
Donald
A. Goldmann, Children's Hospital Boston, Boston, MA
Sponsored jointly by the Pediatric
Infectious Diseases Society and the Pediatric Academic
Societies
8:00am–10:00am
5146—Neonatal
CNS Injury
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
5150—Vascular
Mediators in Persistent Pulmonary Hypertension
PAS Original Science Abstracts -
Platform Session
1:45pm–3:45pm
5500—What's
New in Pediatric Thrombosis
PAS/ASPHO Topic Symposium
Chairs:
Guy Young, Children's Hospital of Orange County and Mattel
Children's Hospital at UCLA, Orange, CA; and Marilyn Manco-Johnson,
Mountain States Hemophilia Treatment Center and University
of Colorado, Aurora, CO
Thrombosis in children is an increasingly recognized
phenomenon in pediatrics largely due to major advances in
the care of critically ill patients and the increased use
of intravascular catheters. As a result of the increased
frequency of thrombosis and increased collaboration among
clinical researchers, there is a significant amount of new
data emerging in the field of pediatric thrombosis. These
data include new knowledge regarding genetic risk factors,
outcome predictors and the use of novel anticoagulants.
This session will include a detailed discussion of genetic
risk factors for thrombosis, including which risk factors
to test for in which patients and how to apply the results
of testing into decision making. A discussion on
traditional versus new anticoagulants will assess the
current and future role of these novel agents in the care
of pediatric patients. Finally, there will be a discussion
on outcome predictors for deep vein thrombosis and how
they influence initial treatment choices such as
anticoagulation and thrombolysis.
Target Audience: Physicians involved in the diagnosis
and management of patients with thromboembolic
complications.
Introduction
Marilyn
J. Manco-Johnson, Chair
Genetic Risk Factors for Thrombosis
Ulrike
Nowak-Gottl, University of Muenster, Muenster, Germany
Novel Anticoagulants
Guy
Young, Children's Hospital of Orange County, Mattel
Children's Hospital at UCLA, Orange County, CA
Outcome Predictors in Deep Vein Thrombosis
Marilyn
J. Manco-Johnson, Chair
Sponsored jointly by the American Society
of Pediatric Hematology/Oncology and the Pediatric
Academic Societies
2:00pm–4:00pm
5521—Regulation
of Alveolar Epithelial Repair—or, How Do We Put It All
Back Together Again
PAS Topic Symposium
Chairs:
Rita Ryan, State University of New York at Buffalo, Women
and Children's Hospital of Buffalo, Buffalo, NY; and Heber
Nielsen, Tufts University School of Medicine, Tufts-New
England Medical Center, Boston, MA
Regulation of alveolar epithelial repair after many
forms of lung injury remains incompletely understood. The
type II cell is an important source of growth factors and
there are autocrine and paracrine mediators that are
altered during the repair process. Type I cells are the
primary covering of the alveolar epithelium, and their
restoration is critical to recapitulate normal repair.
This symposium will focus on the fundamental mechanisms of
epithelial repair after injury and examine connections
with lung development. Finally, relevance to current
clinical disease will be discussed.
Target Audience: Physician and basic scientists
interested in how the alveolar epithelium repairs itself
after injury and the relationship of lung repair with lung
development.
Introduction
Rita
M. Ryan, State University of New York at Buffalo, Women
and Children's Hospital of Buffalo, Buffalo, NY
Heber C. Nielsen, Tufts New England Medical Center,
Boston, MA
Type II Cell Mitogens
Timothy
D. Le Cras, Cincinnati Children's Hospital Medical Center,
Cincinnati, OH
Type II Cell Proliferation During Lung Injury and
Repair
Michael
A. O'Reilly, University of Rochester, Rochester, NY
Type I Cells in Alveolar Repair
Susan
H. Guttentag, Children's Hospital of Philadelphia,
Philadelphia, PA
Apoptosis in Alveolar Epithelial Repair
Lin
L. Mantell, Institute for Medical Research at North
Shore-Long Island Jewish, New York University School of
Medicine, Manhasset, NY
Translating Alveolar Epithelial Repair Fundamentals
to the Bedside
John
S. Torday, Los Angeles Biomedical Research Institute at
Harbor-UCLA Medical Center, Torrance, CA
4:15pm–5:45pm
5702—Identification
of Asthma-Susceptibility Genes and Implications for New
Pharmaceutical Development
PAS State of the Art Plenary
Chair:
Clifford W. Bogue, Yale University School of Medicine, New
Haven, CT
Asthma is rapidly emerging as a major public health
disorder in childhood. Innovative strategies combining
genetic mapping and gene expression profiling are
providing the tools to identify genes that underpin asthma
predisposition. This presentation not only has relevance
for an important pediatric medical topic, but also
establishes a paradigm that can be used for other complex
genetic disorders that affect children.
Target Audience: This session will be of interest to
a broad audience including practicing pediatricians,
geneticists, pulmonologists, pharmacologists, critical
care specialists and allergist/immunologists
Marsha Wills-Karp, Children's Hospital Medical
Center, Cincinnati, OH
Monday, MAY 16
8:00am–10:00am
6132—Clinical
Trials in Perinatal and Neonatal Medicine I
PAS Original Science Abstracts -
Platform Session
3:00pm–5:00pm
6702—Neonatal
Neuropharmacology in 2005
PAS Topic Symposium
Chair:
Faye Silverstein, University of Michigan, Ann Arbor, MI
A critical priority for neonatal medicine is the
challenge of understanding the impact of diverse forms of
therapy on brain development. It remains extremely
challenging to design feasible studies to address this
theme. In infants with underlying neurological disorders
it is particularly difficult to distinguish whether
long-term adverse effects reflect underlying
neuropathology or deleterious effects of a specific
therapy. The three speakers will provide an overview of
current and future approaches to treat the major
neurological disorders that affect neonates and how the
risks and benefits of treatment can be dissected.
Donna Ferriero will discuss current strategies for
selection of neonates for neuroprotection therapy and new
approaches for the development of more effective
neuroprotection interventions. She will discuss mechanisms
of brain injury and repair that are unique to the
developing brain. She will highlight the scientific
rationale for development of combination therapies that
may be most successful in protecting the injured neonatal
brain.
Scott Rivkees will highlight new information about
adenosine pharmacology in the neonatal brain. Caffeine is
a multifunctional drug that blocks adenosine action. High
doses of caffeine exert adverse effects on the developing
brain; however, recent evidence suggests that blocking
adenosine action may reduce certain forms of brain injury
in experimental models. His talk will address influences
of caffeine action and adenosine blockade during
development.
Faye Silverstein will discuss information about the
current treatment of neonatal seizures and strategies for
improving diagnosis and treatment. Her talk will highlight
some of the major unanswered questions about diagnosis and
treatment of neonatal seizures. She will also discuss the
implications of recent basic science findings regarding
risks of anti-convulsant therapy in the developing brain.
Target Audience: Clinicians involved in the treatment
of neonates with neurological disorders and scientists
interested in mechanisms of neonatal brain injury and
repair.
Introduction
Faye
S. Silverstein, University of Michigan, Ann Arbor, MI
Neonatal Neuroprotection: Cocktails and Ice
Donna
M. Ferriero, University of California, San Francisco, CA
Effects of Caffeine and Other Adenosine Antagonists
on Brain Development
Scott
A. Rivkees, Yale School of Medicine, New Haven, CT
Neonatal Seizures: How Can Treatment Be Improved?
Faye
S. Silverstein, University of Michigan, Ann Arbor, MI
Discussion
3:00pm–5:00pm
6732—Neonatal
Hyperoxia and the Lung
PAS Original Science Abstracts -
Platform Session
Tuesday, MAY 17
8:00am–10:00am
7100—Endocrine
Controversies and the Role of Hormone
Replacement/Treatment in the NICU/PICU
PAS/LWPES Topic Symposium
Chairs:
Ram Menon, University of Michigan, Ann Arbor, MI; and
Mitchell Geffner, Children's Hospital of Los Angeles, Los
Angeles, CA
Much remains unknown about the physiology involved in
transition from intra-uterine to extra-uterine life in the
premature or full-term infant. Many strategies have been
employed to manipulate the hormonal milieu of some of our
sickest patients. Assuming adrenal insufficiency in a
critically ill neonate has become fairly routine, despite
precious few data. This symposium draws on the expertise
of endocrinologists and neonatologists and will enlighten
the attendees to some of the practical clinical
controversies that exist in these patients.
Target Audience: Neonatologists, critical care
doctors and endocrinologists.
Impact of Postnatal Glucocorticoids on L-HPA Stress
in Axis Development
Charles
R. Macías Neal, University of Hawaii, John A. Burns
School of Medicine, Honolulu, HI
Sick Euthyroid—Should It Be Treated?
Edmund
F. La Gamma, New York Medical College, Westchester Medical
Center, Valhalla, NY
Adrenal Insufficiency in the PICU/NICU
Delia
M. Vazquez, University of Michigan Medical School, Ann
Arbor, MI
Discussion
Sponsored jointly by the Lawson Wilkins
Pediatric Endocrine Society and the Pediatric Academic
Societies
8:00am–10:00am
7150—Cardiopulmonary
Critical Care
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
7152—Clinical
Trials in Perinatal and Neonatal Medicine II
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
7158—Mechanisms
of Childhood Lung Disease
PAS Original Science Abstracts -
Platform Session
10:15am–11:45am
7301—Genetic
Mechanisms of Respiratory Distress in the Newborn Infant
PAS State of the Art Plenary
Chair:
F. Sessions Cole, Washington University School of
Medicine, St. Louis Children's Hospital, St. Louis, MO
Improved survival of newborn infants with lung
disease has unmasked distinct genetic mechanisms that
contribute to acute, chronic and lethal pulmonary
insufficiency. Mutations in the surfactant protein genes B
and C and a lamellar body transporter gene (ATP-binding
cassette transporter A3 or ABCA3) may disrupt pulmonary
surfactant function and alveolar type 2 pneumocyte
metabolism. After discussing the clinical aspects of the
surfactant protein deficiencies, we will discuss how more
common polymorphisms in the surfactant protein genes may
be related to respiratory distress and our current
understanding of the pathogenetic contribution of
mutations in the ABCA3 gene to both acute neonatal and
chronic interstitial lung disease in children.
Target Audience: Neonatologists, pulmonologists and
geneticists.
Introduction
F.
Sessions Cole, Washington University School of Medicine,
St. Louis Children's Hospital, St. Louis, MO
Clinical Aspects of Surfactant Protein Deficiencies
Aaron
Hamvas, Washington University School of Medicine, St.
Louis Children's Hospital, St. Louis, MO
Polymorphisms in the Surfactant Protein Genes
Mikko
Hallman, University of Oulu, Oulu, Finland
ABCA3 and the Genetic Basis of Interstitial Lung
Disease
Lawrence
M. Nogee, Johns Hopkins School of Medicine, Baltimore, MD
Summary
F.
Sessions Cole, Washington University School of Medicine,
St. Louis Children's Hospital, St. Louis, MO
Supported in part by an unrestricted
educational grant from Dey, LP
12:00pm–1:30pm
Poster
Session IV
PAS Original Science Abstracts -
Poster Session
7400—Critical Care
1:45pm–3:45pm
7602—Pulmonary
Hypertension: Mechanisms and Management
PAS Hot Topic
Chair:
Steve H. Abman, University of Colorado School of Medicine,
Denver, CO
Pulmonary hypertension contributes significantly to
high morbidity and mortality in diverse clinical settings,
including term or near-term newborns with hypoxemic
respiratory failure, premature infants with RDS,
congenital heart disease, idiopathic or primary pulmonary
hypertension and other diseases. Recent advances in
molecular biology, genetics and physiology have led to
novel therapeutic strategies that are now available for
the treatment of severe pulmonary hypertension. This
symposium will present novel mechanisms in the
pathogenesis of pulmonary hypertension, as well as
critical appraisal of treatment options for neonates,
infants and children with pulmonary hypertension. First,
basic molecular and cellular mechanisms that underlie the
development of pulmonary hypertension will be presented.
This will be followed by a discussion of the physiologic
basis for current therapeutic approaches to persistent
pulmonary hypertension of the newborn and ongoing
controversies in patient management. The next speaker will
discuss the use of inhaled nitric oxide (iNO) in premature
infants. Although approved for use in the term or
near-term neonate with hypoxemic respiratory failure, the
potential role for iNO in premature newborns for the
treatment of acute lung disease or the prevention of
bronchopulmonary dysplasia has been highly controversial.
Finally, we will learn of novel treatment strategies for
children with chronic pulmonary hypertension, including
clinical approaches that utilize separate or combined
therapies, such as prostacyclin analogues, endothelin
receptor antagonists and PDE5 inhibitors.
Target Audience: Scientists and clinicians from
diverse clinical backgrounds, including neonatology,
cardiology, pulmonary medicine and critical care who are
involved with newborns and children with acute and chronic
pulmonary hypertension. This symposium will describe
recent advances in the basic science and clinical
management strategies of pulmonary hypertension.
Novel Mechanisms in the Pathogenesis of Pulmonary
Hypertension
Marlene
Rabinovitch, Stanford University School of Medicine,
Stanford, CA
New Insights in the Pathophysiology and Treatment of
PPHN
Robin
H. Steinhorn, Northwestern University Medical School,
Chicago, IL
Controversies in the Use of Inhaled NO in Premature
Newborns
John
P. Kinsella, University of Colorado School of Medicine,
Children's Hospital, Denver, CO
Novel Therapeutic Strategies for the Treatment of
Pulmonary Hypertension
Robyn
J. Barst, Columbia University College of Physicians &
Surgeons, New York, NY
Supported by an unrestricted educational
grant from INO Therapeutics
|
